Underprescription of Step III Opioids in French Cancer Survivors With Chronic Pain: A Call for Integrated Early Palliative Care in Oncology

Chronic pain (CP) is a major concern in cancer survivors. Often under-reported by patients, it is both underassessed and undertreated by care providers. To assess CP prevalence and related treatment in cancer survivors five years after diagnosis and to identify factors associated with prescribing op...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pain and symptom management 2020-04, Vol.59 (4), p.836-847
Main Authors: Janah, Asmaa, Bouhnik, Anne-Déborah, Touzani, Rajae, Bendiane, Marc-Karim, Peretti-Watel, Patrick
Format: Article
Language:English
Subjects:
Access
Bacteriology
Cancer
Cardiology and cardiovascular system
Chronic pain
Emerging diseases
health insurance data
Health status
Human health and pathology
Infectious diseases
Inpatient care
inpatient palliative care
Life Sciences
Medical diagnosis
Medical personnel
Microbiology and Parasitology
Narcotics
Oncology
Opioids
Pain
Palliative care
Parasitology
Prescribing
Prescription drugs
Risk factors
Survivor
Symptom management
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic pain (CP) is a major concern in cancer survivors. Often under-reported by patients, it is both underassessed and undertreated by care providers. To assess CP prevalence and related treatment in cancer survivors five years after diagnosis and to identify factors associated with prescribing opioids among survivors with CP, focusing on access to palliative care (PC). In 2015–2016, we interviewed 4174 French patients diagnosed with cancer five years previously. Combining patient-reported and clinical-reported outcomes together with medicoadministrative data, we studied factors associated with Step II and Step III opioid prescriptions in cancer survivors with CP. We performed multinomial logistic regression adjusting for various covariates, including self-reported health status variables and inpatient PC. Five years after cancer diagnosis, 63.5% of the respondents reported current CP (i.e., pain lasting three months or more). Of these, 64.6% and 14.4% were prescribed at least one Step II or Step III opioid, respectively. Only 1.9% had had inpatient PC since diagnosis. After adjustment for age, gender, clinical and self-reported variables, we found that the latter were more likely to receive Step III opioids (adjusted relative risk ratio 5.33; 95% CI 1.15, 24.58). This study showed a high prevalence of CP five years after cancer diagnosis. Step III opioids were underprescribed but positively associated with inpatient PC. PC access in France remains limited, especially among cancer survivors. Integrating PC in oncology is essential to provide the best cancer-related symptoms management.
ISSN:0885-3924
1873-6513
DOI:10.1016/j.jpainsymman.2019.10.027